INVESTMENT MANAGERS SER TR II Stock Price, News & Analysis

SNPX historically represented Synaptogenix, Inc. on the Nasdaq Capital Market. According to company disclosures and press releases, Synaptogenix was a clinical-stage biopharmaceutical company that had historically worked to develop novel therapies for neurodegenerative diseases. In 2025, the company rebranded and shifted its strategic focus, and its common stock began trading under the new name TAO Synergies Inc. and ticker symbol TAOX. An 8-K filed on June 27, 2025, states that the company filed a certificate of amendment to change its name to TAO Synergies Inc., effective June 26, 2025, and that the common stock would cease trading under the symbol SNPX and begin trading as TAOX on or about July 1, 2025.

For investors researching the historical SNPX symbol, it is important to understand both the company’s biopharmaceutical background and its later transition to a digital asset-focused strategy. Synaptogenix described itself in multiple press releases as an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders. The company conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease. Preclinical studies cited by the company also reported regenerative mechanisms of action for Bryostatin-1 in Fragile X syndrome and other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration granted Orphan Drug Designation to Bryostatin-1 as a treatment for Fragile X syndrome, and the company noted that Bryostatin-1 had already been tested in more than 1,500 people in cancer studies, creating a substantial safety database to inform future trial designs.

Synaptogenix announced several research initiatives while trading under the SNPX symbol. In a June 26, 2024 press release, the company reported that the U.S. Food & Drug Administration had authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis. The company stated that the fully funded, open-label clinical trial would be conducted at the Cleveland Clinic Neurological Institute’s Mellen Center for Multiple Sclerosis and would use high-field MRI technology to identify biomarkers for evaluating Bryostatin-1’s impact on the brain. The company highlighted Bryostatin-1’s mechanism of action as a small molecule that activates protein kinase C (PKC) enzymes involved in maintaining synapse health, learning, and memory, and referenced preclinical work suggesting potential benefits in preventing synapse loss, reducing inflammation, and limiting neurologic deficits.

In a July 18, 2024 press release, Synaptogenix announced a collaboration with LSU Health New Orleans’ Neuroscience Center of Excellence for preclinical testing of a family of polyunsaturated fatty acid (PUFA) analogs as a potential treatment for spinal cord injury. The company stated that it held exclusive rights to these PUFA analogs through a licensing agreement with Cognitive Research Enterprises, Inc. and that a newly issued U.S. patent covered these analogs for use in the treatment of neurodegenerative diseases. According to the company, earlier preclinical testing by its licensor showed positive results for these analogs in slowing or reversing several neurodegenerative disease processes in Alzheimer’s disease, and in promoting synaptogenesis, anti-amyloid and anti-tau effects, and prevention of neuronal death. Synaptogenix characterized these PUFA analogs as next-generation candidates related to its Bryostatin-1 program, with both acting as activators of PKC epsilon (PKC ε) but at different sites on the enzyme.

The company also disclosed activities in cannabinoid-based drug discovery. In a May 7, 2024 press release, Synaptogenix described a partnership with Cannasoul Analytics, in which Synaptogenix had acquired a 25% stake in Cannasoul to support research and development of cannabinoid-based therapeutics. The company reported that this partnership was exploring potential targets for cannabinoid-based therapeutics in multiple indications, including solid tumors, migraine headache, inflammatory bowel disease, and estrogen-related diseases. Synaptogenix highlighted Cannasoul’s expertise in analytical method development for pharmaceutical and botanical research, particularly in cannabis and psilocybin research.

Alongside its research and development activities, Synaptogenix reported several corporate and financial developments while trading as SNPX. On April 24, 2024, the company announced that it had regained compliance with Nasdaq’s minimum bid price requirement after conducting a 1-for-25 reverse split of its common stock, which became effective on April 4, 2024. On September 11, 2024, Synaptogenix announced a $5.0 million financing through the issuance of Series C convertible preferred stock and warrants, describing the transaction as funding potential acquisitions or research on innovative assets. On December 20, 2024, the company reported that its board of directors had formed a special committee to explore strategic opportunities to create and enhance value for investors, supported by what it described as significant cash reserves and a reduced cash burn rate.

In 2025, Synaptogenix disclosed a substantial strategic pivot away from its prior exclusive focus on biopharmaceutical development. In a June 9, 2025 press release, the company announced the launch of a cryptocurrency treasury strategy focused exclusively on the artificial intelligence-related crypto token TAO, which it described as the leading AI token by market capitalization and adoption. The company stated that it planned to acquire TAO tokens as part of a revenue generation strategy targeting staking yield and potential token appreciation. Synaptogenix indicated that this strategy would be funded by its cash reserves and that it viewed TAO as a compelling cryptocurrency based on its fixed supply and the company’s view of growing global demand for AI development.

On June 24, 2025, Synaptogenix announced its initial acquisition of TAO under this crypto treasury strategy and reported that it had selected BitGo to provide qualified custody, staking, and trading services for its TAO holdings. The company stated that BitGo would secure its digital assets in regulated, insured cold storage and facilitate planned TAO acquisitions through affiliated trading platforms, with TAO staked directly from qualified custody to generate yield. The company reported that it had begun to generate revenue through TAO staking and that the initial acquisition was funded by its cash reserves.

This strategic evolution culminated in a rebranding. In a June 26, 2025 press release and in the June 27, 2025 Form 8-K, the company announced that it had changed its name to TAO Synergies Inc. and would adopt the new Nasdaq ticker symbol TAOX effective July 1, 2025. The company described itself in these communications as the first pure-play public company focused on the convergence between cryptocurrency and artificial intelligence. It stated that its digital asset treasury strategy is centered exclusively on acquiring TAO, the native cryptocurrency of the Bittensor decentralized blockchain network for machine learning and AI, with the objective of staking TAO for revenue generation and capital appreciation.

Because of these changes, the SNPX symbol now primarily serves as a historical reference for the period when the company operated and reported as Synaptogenix, Inc. Investors and researchers examining SNPX should consider both the company’s earlier biopharmaceutical programs, including Bryostatin-1 and PUFA analogs, and its later transition to a digital asset treasury model under the TAO Synergies name and TAOX ticker.

Business evolution and focus

Based on the company’s own descriptions, the historical business under SNPX can be viewed in two phases. The first phase centered on biopharmaceutical research and development targeting neurodegenerative diseases. Synaptogenix emphasized clinical and preclinical work on Bryostatin-1, with studies in Alzheimer’s disease and preclinical research in Fragile X syndrome, multiple sclerosis, stroke, traumatic brain injury, and other neurodegenerative conditions. The company also pursued related assets, such as PUFA analogs licensed from Cognitive Research Enterprises, and entered into collaborations with academic and research institutions including LSU Health New Orleans and the Cleveland Clinic.

The second phase, initiated in 2025, involved a strategic shift toward a digital asset treasury strategy focused on TAO. In its June 9, 2025 press release, Synaptogenix described this as a differentiated cryptocurrency treasury strategy focused exclusively on TAO, with plans to acquire TAO tokens and generate revenue through staking. Subsequent disclosures, including the June 24, 2025 press release and the June 27, 2025 Form 8-K, confirm the implementation of this strategy, the engagement of BitGo as custodian, and the rebranding to TAO Synergies Inc. with the TAOX ticker.

Regulatory and listing context

Throughout these transitions, the company remained listed on the Nasdaq Capital Market. The April 24, 2024 press release documents that Synaptogenix regained compliance with Nasdaq’s minimum bid price requirement after a reverse stock split. The June 27, 2025 Form 8-K explains that the name change to TAO Synergies Inc. was effected through a certificate of amendment filed in Delaware and that the ticker symbol would change from SNPX to TAOX without affecting the rights associated with the company’s common stock. The company explicitly stated that the CUSIP for its common stock remained unchanged.

How SNPX relates to TAOX

According to the June 27, 2025 Form 8-K and subsequent press releases, SNPX is the historical trading symbol for the same corporate entity that now operates as TAO Synergies Inc. under the TAOX ticker. The Form 8-K notes that the name change was implemented by amending the company’s certificate of incorporation and that the common stock would transition to trading under the TAOX symbol. Later press releases describe TAO Synergies Inc. as formerly Synaptogenix, Inc. and reiterate that stockholders are not required to take action in connection with the symbol change. For current information about the company’s activities and disclosures after the rebranding, investors should review materials filed and released under the TAOX symbol.

FAQs about SNPX (historical Synaptogenix / TAO Synergies)